MedTrace Logo

Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT06325878 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3500

Last updated 2024-03-26

No results posted yet for this study

Summary

The objective of this study is to characterize the genetic architecture of a large cohort of CIDP patients to evaluate whether specific alleles/haplotypes are implicated in the risk of CIDP, in its clinical and immunological variability, severity, therapeutic response, and association with diabetes and other autoimmune diseases. We will genotype \>700,000 single nucleotide polymorphisms (SNPs) by using the Illumina Global Screening Array (GSA), of approximately 1000 patients with CIDP. About 3500 healthy controls from the Italian population have been already genotyped using GWAS from our genetic department. Alleles/haplotypes will be also compared between patients with typical CIDP and its variants, between CIDP patients with and without specific antibodies, between CIDP patients with and without comorbidities, between CIDP patients with low and high levels of disability and between CIDP patients with and without response to each individual treatment (IVIg, steroids, plasma exchange)

Conditions

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Interventions

GENETIC

Genome-wide association study

Alleles/haplotypes evidence through GWAS will be compared between patients with CIDP and control subjects without CIDP

Sponsors & Collaborators

  • Istituto Clinico Humanitas

    lead OTHER

Principal Investigators

  • Pietro Emiliano Doneddu, MD · Humanitas Research Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-15
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06325878 on ClinicalTrials.gov